Korean J Fam Pract 2020; 10(2): 87-95  https://doi.org/10.21215/kjfp.2020.10.2.87
Coronavirus Disease 2019 (COVID-19): Pandemic and the Challenge of Public Health
Seung-Hwa Lee1, Jong Myoung Kim1,2,3,*
1Department of Family Medicine, Seongnam Citizens Medical Center; 2Public Health Policy Institute, Seongnam Citizens Medical Center; 3COVID-19 Task Force, Seongnam Citizens Medical Center, Seongnam, Korea
Jong Myoung Kim
Tel: +82-31-738-7260, Fax: +82-31-738-7810
E-mail: stuyoo@scmc.kr
ORCID: http://orcid.org/0000-0002-3849-3512
Received: April 16, 2020; Revised: April 16, 2020; Accepted: April 16, 2020; Published online: April 20, 2020.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Infectious diseases caused by the novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), the first outbreak in China, are currently pandemic in the world, including in Korea. Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has not been proven and there has been no proper target medicine and vaccine, so it is virtually unprotected and is a serious health problem. A mitigation strategy that lowers and slows the peak of the epidemic is required to ensure efficient distribution of medical resources and time to development of therapeutic medicines and preventive vaccine. For this, close cooperation between the government and medical practitioners are required, and national prevention and prevention of the spread of the community and preparation for inflow from abroad will be required. In addition, large-scale studies on drugs including hydroxychloroquine, remdesivir, etc., which are known to be effective as therapeutic agents for COVID-19, are required to develop a vaccine for prevention. The authors hope that this review will assist primary care physicians currently engaged in patient care.
Keywords: COVID-19; SARS-CoV-2; 2019-nCoV; Wuhan Coronavirus; Mitigation Strategy
References
  1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. Geneva: World Health Organization;2020 [cited 2020 Mar 21].
  2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus:classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5: 536-44.
    Pubmed KoreaMed CrossRef
  3. Centers for Disease Control and Prevention. Locations with confirmed COVID-19 cases, by WHO region [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2020 [cited 2020 Mar 25].
  4. Viboud C, Grais RF, Lafont BA, Miller MA, Simonsen L; Multinational Influenza Seasonal Mortality Study Group. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect Dis 2005; 192: 233-48.
    Pubmed CrossRef
  5. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178: 53-60.
    Pubmed CrossRef
  6. Rewar S, Mirdha D, Rewar P. Treatment and prevention of pandemic H1N1 Influenza. Ann Glob Health 2015; 81: 645-53.
    Pubmed CrossRef
  7. World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Mar 11].
  8. Fukuda K, Wang R, Vallat B. Naming diseases: first do no harm. Science 2015; 348: 643.
    Pubmed CrossRef
  9. World Health Organization. World Health Organization best practices for the naming of new human infectious diseases [Internet]. Geneva: World Health Organization; 2015 [cited 2020 Mar 28].
  10. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3: 237-61.
    Pubmed KoreaMed CrossRef
  11. Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3' and 5' ends. Virus Res 2015; 206: 120-33.
    Pubmed KoreaMed CrossRef
  12. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16: 69.
    Pubmed KoreaMed CrossRef
  13. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-7.
    Pubmed CrossRef
  14. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207.
    Pubmed KoreaMed CrossRef
  15. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020; 395: 689-97.
    Pubmed KoreaMed CrossRef
  16. Chinese Center for Disease Control and Prevention. Epidemic update and risk assessment of 2019 novel coronavirus [Internet]. Beijing: Chinese Center for Disease Control and Prevention; 2020 [cited 2020 Apr 14].
  17. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill 2020; 25: 2000058.
    Pubmed KoreaMed CrossRef
  18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
    Pubmed KoreaMed CrossRef
  19. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28 [Epub]. https://doi.org/10.1056/NEJMoa2002032.
    Pubmed KoreaMed CrossRef
  20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 Feb 7 [Epub]. https://doi.org/10.1001/jama.2020.1585.
    Pubmed CrossRef
  21. World Health Organization. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19) [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Apr 10].
  22. Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARSCoV2:should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J 2020 Mar 20 [Epub]. https://doi.org/10.1093/eurheartj/ehaa235.
    Pubmed CrossRef
  23. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 Mar 4 [Epub]. https://doi.org/10.1016/j.cell.2020.02.052.
    Pubmed KoreaMed CrossRef
  24. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China:implication for infection prevention and control measures. J Korean Med Sci 2020; 35: e61
    Pubmed KoreaMed CrossRef
  25. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020 Mar 18 [Epub]. https://doi.org/10.1056/NEJMoa2001282.
    Pubmed KoreaMed CrossRef
  26. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2). Clin Infect Dis 2020 Mar 9 [Epub]. https://doi.org/10.1093/cid/ciaa237.
    Pubmed KoreaMed CrossRef
  27. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20 [Epub]. https://doi.org/10.1016/j.ijantimicag.2020.105949.
    Pubmed KoreaMed CrossRef
  28. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382: 929-36.
    Pubmed KoreaMed CrossRef
  29. Centers for Disease Control and Prevention. Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2007 [cited 2020 Apr 10].


This Article

e-submission

Archives